Pediatric Hydroxyurea in Sickle Cell Anemia (PED HUG)

Summary

To determine whether hydroxyurea prevents the onset of chronic end organ damage in young children with sickle cell anemia.

Timeline

Start

1994-04

Primary completion

—

Completion

1997-03

Publications

• Background Phase I/II Multicenter Pediatric Trial of Hydroxyurea (HUG-Kids). Blood, 90 (Suppl 1):Abstract # 1974, 1997.
• Background Kinney TR, Helms RW, O'Branski EE, Ohene-Frempong K, Wang W, Daeschner C, Vichinsky E, Redding-Lallinger R, Gee B, Platt OS, Ware RE. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. Blood. 1999 Sep 1;94(5):1550-4.
• Background Wang WC, Helms RW, Lynn HS, Redding-Lallinger R, Gee BE, Ohene-Frempong K, Smith-Whitley K, Waclawiw MA, Vichinsky EP, Styles LA, Ware RE, Kinney TR. Effect of hydroxyurea on growth in children with sickle cell anemia: results of the HUG-KIDS Study. J Pediatr. 2002 Feb;140(2):225-9. doi: 10.1067/mpd.2002.121383.

Drugs

Indications